Skip to main content
Top
Published in: Neurology and Therapy 6/2023

Open Access 04-10-2023 | Guillain-Barré Syndrome | ORIGINAL RESEARCH

Predicting of Mechanical Ventilation and Outcomes by Using Models and Biomarker in Guillain-Barré Syndrome

Authors: Jiajia Yao, Rumeng Zhou, Yue Liu, Yin Liu, Qian Cao, Zuneng Lu

Published in: Neurology and Therapy | Issue 6/2023

Login to get access

Abstract

Background

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy. The Erasmus GBS Respiratory Insufficiency Score (EGRIS) and the modified Erasmus GBS Outcome Score (mEGOS) are prognostic models used in the prediction of mechanical ventilation and outcome. Thus far, there are only few biomarkers for the prognosis prediction of GBS patients, and albumin level is one that is promising.

Methods

Patients diagnosed with GBS from 2013 to 2022 at Renmin Hospital, Wuhan University, China, were included. Patients hospitalized between 2016 and 2022 underwent short- and long-term follow-ups. The correlations between EGRIS/mEGOS and mechanical ventilation and outcome were evaluated. Serum albumin level was examined the day after admission. Furthermore, we also investigated whether the level of serum albumin was useful in predicting disease severity or poor outcome.

Results

In all, 145 patients were enrolled. Nineteen patients (13.1%) who required mechanical ventilation had higher Hughes GBS disability score (HGDS) at admission and discharge (P < 0.05 and P < 0.0001, respectively), shorter time from onset to admission and treatment (P < 0.01 and P < 0.001, respectively) and longer hospital stays (P < 0.001) than patients who did not require mechanical ventilation. High EGRIS scores were linked with the need for mechanical ventilation (r = 0.427, P < 0.001, AUC = 0.623). Seventy-one patients were admitted between 2016 and 2022. Of these, 65 patients had a 4-week follow-up and 61 had a 6-month follow-up. Higher mEGOS scores at admission and 7 days after admission significantly correlated with short- (P < 0.0001 and P < 0.0001) and long-term (P < 0.05 and P < 0.05) outcomes, respectively. No significant difference in outcome was found between different subtypes (4 weeks [P = 0.099] and 6 months [P = 0.172]). Patients with lower albumin level tended to have higher HGDS (at admission P < 0.05, at nadir P < 0.001, and at discharge P < 0.001) and higher properties of the need of mechanical ventilation (P < 0.05) and ICU stay (P < 0.05) than those with normal albumin levels. Those with low albumin levels were also unable to walk independently at 6 months (P < 0.01).

Conclusions

mEGOS scores predicted the outcomes of GBS patients in China, and EGRIS score predicted the need for mechanical ventilation in these patients. Albumin level at admission correlated well with disease severity and outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–28.CrossRefPubMed Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–28.CrossRefPubMed
2.
go back to reference van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):939–50.CrossRefPubMed van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7(10):939–50.CrossRefPubMed
3.
go back to reference Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–77.CrossRefPubMed Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–77.CrossRefPubMed
4.
go back to reference Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012;83(7):711–8.CrossRefPubMed Rajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2012;83(7):711–8.CrossRefPubMed
5.
6.
go back to reference Arami MA, Yazdchi M, Khandaghi R. Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. Ann Saudi Med. 2006;26(1):22–7.CrossRefPubMedPubMedCentral Arami MA, Yazdchi M, Khandaghi R. Epidemiology and characteristics of Guillain-Barré syndrome in the northwest of Iran. Ann Saudi Med. 2006;26(1):22–7.CrossRefPubMedPubMedCentral
7.
go back to reference Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011;76(11):968–75.CrossRefPubMedPubMedCentral Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011;76(11):968–75.CrossRefPubMedPubMedCentral
8.
go back to reference Strauss J, Aboab J, Rottmann M, Porcher R, Polito A, Ikka L, et al. Plasma cortisol levels in Guillain-Barré syndrome. Crit Care Med. 2009;37(8):2436–40.CrossRefPubMed Strauss J, Aboab J, Rottmann M, Porcher R, Polito A, Ikka L, et al. Plasma cortisol levels in Guillain-Barré syndrome. Crit Care Med. 2009;37(8):2436–40.CrossRefPubMed
9.
go back to reference Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N. Indicators of rapid clinical recovery in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2001;70(4):560–2.CrossRefPubMedPubMedCentral Kuwabara S, Mori M, Ogawara K, Hattori T, Yuki N. Indicators of rapid clinical recovery in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry. 2001;70(4):560–2.CrossRefPubMedPubMedCentral
10.
go back to reference Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJ, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781–7.CrossRefPubMed Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJ, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781–7.CrossRefPubMed
11.
go back to reference Axelsson M, Sjögren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study. Acta Neurol Scand. 2018;138(2):143–50.CrossRefPubMed Axelsson M, Sjögren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study. Acta Neurol Scand. 2018;138(2):143–50.CrossRefPubMed
12.
go back to reference Notturno F, Caporale CM, De Lauretis A, Uncini A. Glial fibrillary acidic protein: a marker of axonal Guillain-Barrè syndrome and outcome. Muscle Nerve. 2008;38(1):899–903.CrossRefPubMed Notturno F, Caporale CM, De Lauretis A, Uncini A. Glial fibrillary acidic protein: a marker of axonal Guillain-Barrè syndrome and outcome. Muscle Nerve. 2008;38(1):899–903.CrossRefPubMed
13.
go back to reference Petzold A, Hinds N, Murray NM, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology. 2006;67(6):1071–3.CrossRefPubMed Petzold A, Hinds N, Murray NM, Hirsch NP, Grant D, Keir G, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology. 2006;67(6):1071–3.CrossRefPubMed
14.
go back to reference Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134–42.CrossRefPubMed Chiò A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134–42.CrossRefPubMed
15.
go back to reference Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, et al. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. J Peripher Nerv Syst. 2017;22(4):433–9.CrossRefPubMed Yamagishi Y, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, et al. Markers for Guillain-Barré syndrome with poor prognosis: a multi-center study. J Peripher Nerv Syst. 2017;22(4):433–9.CrossRefPubMed
16.
go back to reference Papri N, Doets AY, Mohammad QD, Endtz HP, Lingsma HF, Jacobs BC, et al. Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh. Ann Clin Transl Neurol. 2022;9(8):1264–75.CrossRefPubMedPubMedCentral Papri N, Doets AY, Mohammad QD, Endtz HP, Lingsma HF, Jacobs BC, et al. Validation and adjustment of modified Erasmus GBS outcome score in Bangladesh. Ann Clin Transl Neurol. 2022;9(8):1264–75.CrossRefPubMedPubMedCentral
17.
go back to reference Tan CY, Razali SNO, Goh KJ, Shahrizaila N. The utility of Guillain-Barré syndrome prognostic models in Malaysian patients. J Peripher Nerv Syst. 2019;24(2):168–73.CrossRefPubMed Tan CY, Razali SNO, Goh KJ, Shahrizaila N. The utility of Guillain-Barré syndrome prognostic models in Malaysian patients. J Peripher Nerv Syst. 2019;24(2):168–73.CrossRefPubMed
18.
go back to reference Qinrong H, Yuxia C, Ling L, Huayu L, Lei X, Xiaoli L, et al. Reliability and validity of prognostic indicators for Guillain-Barré syndrome in children. Dev Med Child Neurol. 2022;65(4):563–70.CrossRefPubMed Qinrong H, Yuxia C, Ling L, Huayu L, Lei X, Xiaoli L, et al. Reliability and validity of prognostic indicators for Guillain-Barré syndrome in children. Dev Med Child Neurol. 2022;65(4):563–70.CrossRefPubMed
19.
go back to reference Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMed Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol. 1990;27(Suppl):S21–4.CrossRefPubMed
20.
go back to reference Wakerley BR, Uncini A, Yuki N. Guillain-Barré and Miller Fisher syndromes–new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44.CrossRefPubMed Wakerley BR, Uncini A, Yuki N. Guillain-Barré and Miller Fisher syndromes–new diagnostic classification. Nat Rev Neurol. 2014;10(9):537–44.CrossRefPubMed
21.
go back to reference Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597–605.CrossRefPubMed Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597–605.CrossRefPubMed
22.
go back to reference Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998;44(5):780–878.CrossRefPubMed Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998;44(5):780–878.CrossRefPubMed
24.
go back to reference van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6(7):589–94.CrossRefPubMed van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6(7):589–94.CrossRefPubMed
25.
go back to reference Doets AY, Lingsma HF, Walgaard C, Islam B, Papri N, Davidson A, et al. Predicting outcome in Guillain-Barré syndrome: international validation of the modified Erasmus GBS outcome score. Neurology. 2022;98(5):e518–32.CrossRefPubMedPubMedCentral Doets AY, Lingsma HF, Walgaard C, Islam B, Papri N, Davidson A, et al. Predicting outcome in Guillain-Barré syndrome: international validation of the modified Erasmus GBS outcome score. Neurology. 2022;98(5):e518–32.CrossRefPubMedPubMedCentral
26.
go back to reference Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. Med J Aust. 2018;208(4):181–8.CrossRefPubMed Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis. Med J Aust. 2018;208(4):181–8.CrossRefPubMed
27.
go back to reference Verma R, Chaudhari TS, Raut TP, Garg RK. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS). J Neurol Sci. 2013;335(1–2):105–11.CrossRefPubMed Verma R, Chaudhari TS, Raut TP, Garg RK. Clinico-electrophysiological profile and predictors of functional outcome in Guillain-Barre syndrome (GBS). J Neurol Sci. 2013;335(1–2):105–11.CrossRefPubMed
28.
go back to reference Cheng Y, Liu K, Li C, Zhang W, Wu X, Fang S. Risk factors for mechanical ventilation in patients with Guillain-Barré syndrome. Neurocrit Care. 2022;37(1):121–8.CrossRefPubMed Cheng Y, Liu K, Li C, Zhang W, Wu X, Fang S. Risk factors for mechanical ventilation in patients with Guillain-Barré syndrome. Neurocrit Care. 2022;37(1):121–8.CrossRefPubMed
29.
go back to reference Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol. 1988;23(4):354–9.CrossRefPubMed Cornblath DR, Mellits ED, Griffin JW, McKhann GM, Albers JW, Miller RG, et al. Motor conduction studies in Guillain-Barré syndrome: description and prognostic value. Ann Neurol. 1988;23(4):354–9.CrossRefPubMed
30.
go back to reference Group TIG-BS. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain. 1996;119(6):2053–25061.CrossRef Group TIG-BS. The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain. 1996;119(6):2053–25061.CrossRef
31.
go back to reference Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China. PLoS One. 2015;10(7): e0133520.CrossRefPubMedPubMedCentral Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China. PLoS One. 2015;10(7): e0133520.CrossRefPubMedPubMedCentral
32.
go back to reference González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 2013;13:95.CrossRefPubMedPubMedCentral González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 2013;13:95.CrossRefPubMedPubMedCentral
33.
go back to reference Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006;5(12):1021–8.CrossRefPubMed Durand MC, Porcher R, Orlikowski D, Aboab J, Devaux C, Clair B, et al. Clinical and electrophysiological predictors of respiratory failure in Guillain-Barré syndrome: a prospective study. Lancet Neurol. 2006;5(12):1021–8.CrossRefPubMed
34.
go back to reference Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC. Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barré syndrome. JAMA Neurol. 2017;74(2):189–96.CrossRefPubMed Fokkink WR, Walgaard C, Kuitwaard K, Tio-Gillen AP, van Doorn PA, Jacobs BC. Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barré syndrome. JAMA Neurol. 2017;74(2):189–96.CrossRefPubMed
35.
go back to reference Shalman A, Savir S, Mechnik Steen Y, Ovanyan A, Boniel N, Koyfman L, et al. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS). J Clin Neurosci. 2020;74:247–9.CrossRefPubMed Shalman A, Savir S, Mechnik Steen Y, Ovanyan A, Boniel N, Koyfman L, et al. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS). J Clin Neurosci. 2020;74:247–9.CrossRefPubMed
36.
go back to reference Rothschild MA, Oratz M, Schreiber SS. Regulation of albumin metabolism. Annu Rev Med. 1975;26:91–104.CrossRefPubMed Rothschild MA, Oratz M, Schreiber SS. Regulation of albumin metabolism. Annu Rev Med. 1975;26:91–104.CrossRefPubMed
Metadata
Title
Predicting of Mechanical Ventilation and Outcomes by Using Models and Biomarker in Guillain-Barré Syndrome
Authors
Jiajia Yao
Rumeng Zhou
Yue Liu
Yin Liu
Qian Cao
Zuneng Lu
Publication date
04-10-2023
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 6/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-023-00546-w

Other articles of this Issue 6/2023

Neurology and Therapy 6/2023 Go to the issue